РАК ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ
(значение проблемы, возможности лечения)
Гарин А.М., Базин И.С., 1999
ЛИТЕРАТУРА
1. Цитировано по Douglass H.O., Kim S.Y., Meropol N.J. Neoplasms of the exocrine pancreas. In "Cancer Medicine" Eds.Holland J.F. et.al., 1997, Baltimore, pp.1989-2017.
2.Янишевский В.И. Рак поджелудочной железы, печени, желчного пузыря и внепеченочных желчных протоков. В кн. "Ранняя диагностика рака", М., 1948, 95-107.
3. Лепорский Н.И. Болезни поджелудочной железы. М., 1951.
4. Виноградов В.В. Опухоли и кисты поджелудочной железы. М., 1959.
5. Лидский А.Т. Хирургические заболевания печени и желчевыводящей системы М., 1963.
6. Шелагуров А.А. Болезни поджелудочной железы. М., 1970.
7. Вишневский А.А., Ульманис Я.Л., Гришкевич Э.В. Желчеотводящие анастомозы. М., 1972.
8. Шалимов А.А. Болезни поджелудочной железы и их хирургическое лечение. М., 1970.
9. Блохин Н.Н., Итин А.Б., Клименков А.А. Рак поджелудочной железы и внепеченочных желчных путей. М., 1982.
10. Parkin D.M., Pizani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J.Canc. 1993, 54:594-606.
11. Muir C., Waterhouse J., Mack T., et.al. Cancer Incidence in Five continents v.5, JARC Publ.88, 1988.
12. Facts and figures of cancer in the European community. Eds Esteve I., et.al., 1993, Lyon, p.26.
13. Wingo P.A., Tong T., Bolden S. Cancer statistics 1995. Can.j.clin., 1995; 45:8-30.
14. Сancer FACTS a: Figures - 1999. American Cancer Society
15.Трапезников Н.Н., Аксель Е.М. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1996 г. М., 1997.
16.Wynder E.L., Mabuchi K., Maruchi N. Et.al. Epidemiology of cancer of the pancreas. J.Nat.Canc. Inst. 1973; 50:645-667
17.Chadirian P., Simard A., Baillargeon J. Tabacco, alcohol and coffee and cancer of the pancreas. Cancer 1991; 67:2264-2270.
18.Bueno de Mesquita N.B., Maisonneuve P, Moerman C.J. Life-time history of smoking and exocrine carcinoma of the pancreas. A population based case-control study in the Netherlands. Int.j.Canc.; 1991 , 49:816.
19.Fraumeni J.F. Cancer of the pancreas and biliary tract: Epidemiological considerations. Canc.Res., 1975: 35:3437-3446.
20.Wynder E.L. An epidemiological evaluation of the causes of cancer of the pancreas. Canc.Res. 1975; 35:2228-2233.
21. Kastan M.B., Onyekwere O., Sidransky D., et.al. Participation of p-53 protein in the cellular response to DNA damage. Canc.Res.1991; 51:6304-6311.
22. Hoffman D., Rivenson A., Chung F.L. et.al. Nicotine-derived N-nitrosamines and their relevance in tobacco carci-nogenesis. Crit.Rev.Tox. 1991; 21:305-311.
23.Falk R.T., Pickle R.W., Fontham E.T. et.al. Life-style risk factors for pancreatic cancer in Louisiana: A case -control study. Am.j.Epid.1988, 128:324-336.
24.Mack T.M., Yu M.C., Hanisch R., et.al. Pancreas cancer and smoking, beverage consumption, and past medical history. J.Nat.Canc.Inst. 1986; 76:49-68.
25.Raymond L., Infante F., Tuyns A.J. et.al. Alimentation et cancer du pancreas. Gastr.Clin.Biol. 1987;11:488-492.
26.O'Connor T.P., Roebuck B.D., Peterson E., Campbell T.C. Effect of dietary intake of fish proteins on the development of L-azaserine induced preneoplastic lesions in the pancreas. J.Nat.Canc. Inst. 1985; 75:959-962.
27. Norell S.E., Ahibom A., Erwarld R., et.al Diet and pancreatic cancer: A case-control study/ Am.j.Epid.1986; 124:894-902.
28. Heuch I., Kvale G., Jacobsen B.K.et.al. Use of alcohol, tobacco and coffee and risk of pancreatic cancer. Br.j.Canc. 1983; 48:637-643.
29. Hakulinen T., Lehtimaki L., Lehtonen M., et.al. Cancer morbidity among two male cohorts with increased alcohol consumption in Finland. J.Nat.Canc.Inst. 1974; 52:1711-1714.
30 .Monson R., Lyon J. Proportional mortality among alcoholics. Canc. 1975; 36:1077-1079.
31. Okuda K., Ohishi K. Pancreatic cancer and alcohol. Clin.Gastr. 1981; 10:479-484.
32. Mills P.K., Beeson L., Abbey D.E., et.al. Dietary habits and past medical history as related to fatal pancreas cancer risk among adventists. Canc.1988; 61:2578-2585.
33. Gold E.B., Gordis L., Diener M.D., et.al. Diet and other risk factors for cancer of the pancreas. Canc.1985; 55:460-467.
34.Ahlgren J.D. Epidemiology and risk factors in pancreatic cancer. Sem.in Oncol. 1996; 23:241-250.
35. MacMahon B., Yen S., Trichopoulos D., et.al. Coffee and cancer of the pancreas. N.Engl.j.Med.1981; 304:630-633.
36. Binstock M., Krakow D., Stamler J., et.al. Coffee and pancreatic cancer: An analysis of international mortality data. Am j.Epid. 1983; 118:630-640.
37. Clavel F., Benhamon E., Auquier A.,et.al. Coffee, alcohol, smoking and cancer of the pancreas: a case-control study. Int.j.Canc. 1989; 43:17-21.
38. Kinlen L.J., McPherson K Pancreas cancer and coffee and tea consumption. A case-control study. Br.j.Canc. 1984; 49:93-96.
39. Mancuso T., El-Attar A. Cohort study of workers exposed to betanaphthylamine and benzidine. J.Occup.Med. 1967; 9:277.
40. Li F.P., Fraumeni J.T., Mantel M.A., Miller R.W. Cancer mortality among chemists. J.Nat.Canc.Inst. 1969; 43:1159.
41`. Garabrani D.H., Held J., Langholz B., et.al. DDT and related compounds and risk of pancreatic cancer. J.Nat.Canc.Inst. 1992; 84:764-771.
42. Lynch H.T. Genetics and pancreatic cancer. Arch.Surg. 1994; 126:266.
43. Chadirian P., Simard A., Baillargeon J. Familial aggregation of pancreatic cancer a population-based case -control study. Proc.ASCO 1988; ab.257.
44. Gullo L., Pezzili R., Morselli-Labate A.M., et.al. Diabetes and the risk of pancreatic cancer. N.Engl.Med. 1994; 331:81-84.
45.Karmody A., Kyle J. The association between carcinoma of the pancreas and diabetes mellitus. Br.j.Surg.1969; 56:362-364.
46. Lowenfeis A.B., Maisonnerve P., Cavallini G., et.al. An International Pancreatitis Study Group. Pancretitis and the risk of pancreatic cancer. N.Engl.j.Med.1993; 328:1433.
47.Mainz D., Webster P.D. Pancreatic carcinoma - a review of etiologic considerations. Am.j.Dig.Dis 1974; 19:459-464.
48. Offerhaus G.J.A., Tersmette A.C., Tersmette K., et.al. Gastric pancreatic and colorectal carcinogenesis following remote peptic ulcer surgery. Mod.Pathol. 1988; 1:352-356.
49. Borch K., Kullman E., Hallhagen S., et.al. Increased incidence of pancreatic neoplasia in pernicious anemia. World j.Surg. 1988; 12:866-867.
50.Upp J.R., Olson D., Poston G.J., et.al. Inhibition of growth of two human pancreatic adenocarcinoma in vivo by somatostatin analog Sms 201-995. Am. J.Surg 1984; 142:308-311.
51.Jansen J.B.M. Cholecystokinin and pancreatic cancer. Scand.j.Gastr. 1988; 22(suppl 154):103-106.
52. Howatson A.G., Carter D.C. Pancreatic carcinogenesis - effect of secretin in the hamster- nitrosoamine model. J.N.Canc .Inst. 1987; 78:101-103.
53. Redston M.S., Caldas C., Seymour A.B., et.al. P-53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tract in DNA microdeletions. Canc.Res. 1994; 54:1005-1014.
54. Nakamori S., Yashima K., Murakami Y., et.al Association p-53 gene mutations with short survival in pancreatic adeno-carcinoma. Jpn.j.Canc.Res. 1996;86:174-181.
55. Moskaluk C., Kern S. Molecular genetics of pancreatic cancer. In "Pancreatic Cancer". Ed. Reber H. New.Jersey 1998, pp.3-20
56. Bos J.L. Ras oncogens in humar cancer a review. Canc.Res. 1998;49:4682-4689.
57. Motojima K., Urano T., Nogato Y., et.al. Detection of point mutations in the kirsten-ras oncogene provides evidence for the multicentricity of pancreatic cancer. Ann.Surg. 1993; 217:138.
58. Nakamori S., Okami J., Shiozaki K., et.al. K-ras gene mutations in plasma DNA are potential prognostic indicators for patients with pancreatic cancer. Proc.ASCO, 1999, ab. 967.
59. Satoh K., Sasano H., Shimosegawa T., et.al. An immunohistochemical study of the C-erb. B-2 oncogene product in intraductal mucin-hypersecretive neoplasms and in ductal cells of the pancreas. Canc. 1993; 72:51.
60. Alexandrow M.G., Moses H.L. Transforming growth factor beta and cell cycle regulation. Canc.Res. 1995; 55:1452-1457.
61. Caldas C., Hahn S.A., da Costa L.T., et.al. Frequent somatic mutations and homozygous deletions of the p-16 (MTSI) gene in pancreatic adenocarcinoma Nat.Gen. 1994;8:27-31
62. Yamanaka Y., Friess H., Kobrin H.S. Coexpression of epidermal growth factor receptor and liganda in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticanc.Res. 1993; 13:565-570.
63. Ishiwata T., Bergman U., Kornmann M., et.al. Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas 1997; 15:367-373.
64. Porschen R., Remy U., Bevers G., et.al Prognostic significance of DNA ploidy in adenocarcinoma of the pancreas. A flow cytometria study of paraffin embedded specimens. Canc. 1993; 71:3841.
65. Cubilla A.L., Fitzgerald P.J., Fortner J.C. Pancreas cancerduct cell adenocarcinoma: survival in relation to site, size, stage and type of therapy. J.Surg.Oncol. 1978; 10:465-482.
66. Morohoshi T., Held G., Kloppel G. Exocrine pancreatic tumors and their histological classification: A study based оn 167 autopsy and 97 surgical cases. Histopath. 1983; 7:64-66.
67. Brennan M.F., Kinsella T., Friedman M. Cancer of the pancreas. In "Cancer Principles a Practice of Oncology". Eds.DeVita VT., et.al. 1989, pp.800-836.
68. Wanabe T., Miyashita T., Ohishio G., et.al. Small carcinoma of the pancreas clinical and pathologic evaluation in 17 patients. Canc. 1988; 62:135.
69. Wilentz R.E., Slebos R.J.C., Hruban R.H. Screening for pancreatic cancer using techniques to detect altered gene products . In "Pancreatic Cancer" Ed. Reber H.A., 1998, pp.113-136.
70. Cancer of the Pancreas Task Force: staging of cancer of the pancreas. Canc.1981;47:1631.
71.Fortner J.G. Regional pancreatectomy for cancer of the pancreatic ampulla with other related sites. Tumor staging and results. Ann Surg. 1984; 199, 418.
72. Horton J. Dominant symptoms and signs of pancreatic carcinoma. Curr.Conc. in Oncol. 1989; 1:37.
73.Go V.L.W., Taylor W.F., Di Magno E.P. Efforts at early diagnosis of pancreatic cancer. The Mayo Clinic Experience. Canc.1981; 47:1698.
74.Fras J., Litin E.M., Pearson J.S. Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. Am.j.Psych. 1967; 123:1553.
75.Kalsen M.H., MacIntyre J.M., Barkin J. Pancreatic cancer-assessment of prognosis by clinical presentation. Castr. 1983; 84:1202.
76. Fitzgerald P.J., Fortner J.G., Watson R.C. The value of diagnostic aids in detecting pancreatic cancer. Canc. 1978; 41:868.
77. Neiderau C., Sonnenberg B., Muller J.E., et.al. Sonographic measurements of the normal liver, spleen, pancreas and portal vein. Radiol. 1983;149:537.
78. Fernandez-del Castillo C., Warshaw A.L. Diagnosis and preoperative evaluation of pancreatic cancer, with implications for management. Garstr.Clin.North.Am 1990;19:915-933.
79. Frank B.B. Clinical evaluation of Jaundice: a guideline of the patient care committee of the American Gastroenterological Association. Jama 1989, 262:3031-3034.
80. Ward E.M., Stephens D.H., Sheedy P.F. Computed tomographic characteristics of pancreatic carcinoma: An analysis of 100 cases. Radiol. 1983; 3:547-565.
81. Freeng P.C., Traverso L.W., Ryan J.A. Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am.j.Surg. 1993; 165:600-606.
82. Toshifumi G., Matsui O., Kadoye M., et.al. Small pancreatic adenocarcinomas; efficacy of MK imaging with fat suppression and gadolinium enhancement. Radiol. 1994; 193:683-688.
83. Hall T.J., Blackstone M.O., Cooper M.J.et.al. Prospective evaluation of endoscopic retrograde cholangiopancreatography in the diagnosis of periampullary cancer. Ann.Surg. 1978; 187:313.
84. Fockens P., Huibregtse K. Staging of pancreatic and ampullary cancer by endoscopy. Endosc.,1993; 25:52-57.
85. Moossa A.R., Levin B. The diagnosis of "early" pancreatic cancer- the university of Chicago experience . Canc. 1981; 47:1688.
86. Cuesta M.A., Meijer S., Borgstein P.J. et.al. Laparoscopic ultrasonography for hepatobiliary and pancreatic malignancy . Br.j.Surg. 1993; 80:1571-1574
87. John T.G., Greig J.D., Crosbie J.L., et.al. Superior staging of liver tumors with laparascopy and laparascopic ultrasound. Ann.Surg. 1994; 220:711-719.
88. Hyoty M.K., Mattila J.J., Salo K., et.al. Intraoperative fine needle aspiration cytological examination of pancreatic lesions. Surg.Gyn.Obst. 1991; 173:193-197.
89. Ferrari A.P., Lichtenstein D.R., Sivka A., et.al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastr.Endogc. 1994; 40:140.
90. Rollhauser C., Steinberg W. Tumor antigens in pancreatic cancer. In "Pancreatic Cancer" . Ed.Reber H.A., 1998 Humane Press
91. Aziz D.C. Use and interpretation of laboratory tests in oncology 1999, pp.55-56
92. Steinberg W. The clinical utility of the Ca-19-9 tumorassociated antigen. Am j.Gastr. 1990; 85:350-355.
93. Malesci A., Tommasini M.A., Bonato C., et.al. Determination of Ca-19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroent. 1989; 92:60-67.
94. Piantino P., Andriulli A., Gindro T., et.al. Ca-19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am j.Gastr. 1986; 8:346.
95. Steinberg W.M., Gelfand R., Anderson K.K., et.al. Comparison of the sensitivity and specificity of the Ca-19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroent. 1986; 90:343.
96. Haglund C., Roberts P.J., Jalanko H., Kuusela P. Tumor markers CA-19-9 and Ca 50 in digestive tract malignancies. Scand.j.Gastr. 1992; 26:169-173
97. Mahvi D.M., Meyers W.S., Bost R.C., et.al. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody in carcinoma of the pancreas. Ann. Surg. 1985; 202-440.
98. Robles-Diaz G., Diaz-Sauchez V., Mendez J.P. et.al. Low Serum testosterone/dihydrotestosterone ratio in pancreatic carcinoma. Pancreas 1987; 2:684-687.
99. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Canc. 1987; 60:2284-2303.
100. Nitecki S.S., Sarr M.G., Colby T.V., et.al. Long-term survival after resection for ductal adenocarcinona of the pancreas. Is it really improving? Ann Surg. 1995; 221:59-66.
101. Yeo C.J., Cameron J.K., Lillemoe K.D., et.al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann.Surg. 1995; 221:721-733.
102. Trede M., Schwall G., Saeger H. Survival after pancreaticoduodenectomy:118 consecutive resections without an operative mortality. Ann.Surg. 1990; 211:447-458.
103. Norlander A., Kalin B., Sundblad R. Effect of percutaneous transhepatic drainage upon liver function and postoperative mortality. Surg.Gyn.Obst. 1982; 155:161.
104. Gundry S.R., Strodel W.E., Knol J.A., et.al. Efficacy of preoperative biliary tract decompression in patients with obstructive jaundice. Arch.Surg. 1984; 119:703.
105. McPherson G.A., Benjamin I.S., Hodgson H.J., et.al. Preoperative percutaneous transhepatic biliary drainage:The results of a controlled trial. Br.j.Surg. 1984; 71:371-375.
106. Pitt H.A., Gomes A.S., Lois J.F., et.al. Does preoperative percutaneous biliary drainage operative risk or increase hospital cost? Ann.Surg. 1985; 201:545-553.
107. Pisters P.W.T., Lee J.A., Evans D.B. Standard forms of pancreatic resection . In "Pancreatic Cancer". Ed.Reber H.A., 1998, pp.181-199.
108. Fuhrman G.M., Leach S.D., Staley C.A., et.al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoms adherent to the superior mesenteric- portal vein confluence. Ann.Surg.1996; 223:152-164.
109. Grace P.A., Pitt H.A., Longmire W.P. Pylorus preserving pancreaticoduodenectomy: an overview. Br.j.Surg. 1990; 77:968-974.
110. Lillemoe K.D. Current management of pancreatic carcinoma. Ann.Surg.1995; 221:133-148.
111. McGrath P.C., Sloan D.A., Kenady E. Surgical management of pancreatic carcinoma. Sem.Oncol., 1996:23:2, 200-212.
112. Geer R.J., Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am.j.Surg. 1993; 165:68-73.
113. Патютко Ю.И., Котельников А.Г. Рак поджелудочной железы: диагностика и хирургическое лечение на современном этапе. Анналы хирург.гепатологии 1998, 3;1:96-111
114. Kummerle F., Ruckert K., Surgical treatment of pancreatic cancer. World Surg. 1984; 8:889-894.
115.Van Heerdan J.A., ReMine W.H., Weiland L.H., et.al. Total pancreatectomy for ductal adenocarcinoma of the pancreas Mayo clinic experience. Am j.Surg. 1981; 142:308-311.
116. Fortner J.C. Regional resection of cancer of the pancreas: a new surgical approach. Surg. 1973, 73:658-662.
117. Fortner J.G. Regional pancreatectomy for cancer of the pancreas, ampulla and other related sites. Ann Surg. 1984; 199:418-425.
118. Manabe T., Ohshio G., Baba N., wt.al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Canc. 1989; 64:1132-1137.
119. Satake K., Nishiwaki H., Yokomatsu H. Et.al. Surgical curability and prognosis for standard versus extended resections for T-1 carcinoma of the pancreas. Surg.Gyn. Obstr. 1992; 175:259-265.
120. Geer R.J., Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am j.Surg. 1993; 168:68-73.
121. Singh S.M., Longmire W.P., Reber H.A. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg. 1990; 212:132-139.
122. Забазный Р.П. Операции на органах билиопанкреатодуоденальной зоны у больных, перенесших лечение по поводу различных злокачественных опухолей. Автореф. докт.дисс. М., 1999
123. Wong R.C.K., Carr- Locke D.L. Endoscopic stents for palliation in patients with pancreatic cancer. In "Pancreatic Cancer" Ed.Reber H., 1998,pp.235-252.
124. Weaver D.W., Wiencek R.G., Bouwman D.L., et.al. Gastrojejunostomy:Is it helpful for patients with pancreatic cancer? Surg. 1987; 102:608-613.
125. Wongsuwanporn T., Basse E. Palliative surgical treament of sixty-eight patients with carcinoma of the head of the pancreas. Surg.Gyn.Obstr. 1993; 156:73-75.
126. Malangoni M.A., McCoy M.D., Richardson J.D., et.al. Effective palliation of malignant biliary duct obstruction. Ann Surg. 1985; 201:554-559.
127. Smilanich R.P., Hafner G.H. Complications of biliary stents in obstructive pancreatic malignancies. A case report and review. Dig.Dis.Sci. 1994; 39:2645-2649.
128. Maetani I., Ogawa S., Hoshi H., et.al. Self-expanding metal stents for palliative treatment of malignant biliary and duodenal stenoses. Endosc. 1994;26:703-704.
129 .Lillemoe K.D., Cameron J.L., Kaufman H.S., et.al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg. 1993; 217:447-457.
130. Moertel C.G., Reitemeier R.J. Advanced Gastrointestinal cancer clinical management and chemotherapy NY, 1969, p.7.
131. Maity A., Kao G.D., Muschel R.J., McKenna W.G. Potential molecylar targets for manipulating the radiation response. Int.j.Rad.Oncol.,Biol. Phys. 1997;37:639-653.
132. Miller T.R., Fuller L.M. Radiation therapy of cancer of the pancreas. Report on 91 cases. Am j. Roentg. 1958; 80:787-792.
133. Sindelar W.F., Kinsella T.J. Randomized trial of intraoperative therapy in resected carcinoma of pancreas. Int.j.Rad.Oncol. Biol.Phys. 1986; 12:148.
134. Dowsett J.F., Russell R.C.G. Tumors of the pancreas. In "Oxford Textbook of oncology" Ed.Peckham et.al.,1996, pp.1177-1201
135. Rich T.L. Radiation therapy for pancreatic cancer. In "Pancreatic Cancer". Ed.Reber H.A.. Humane Press 1998, pp.281-294.
136. Coja L., Hoffman J., Scher R., et.al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int.Rad.Oncol. Biol.Phy. 1994; 30:161-167.
137. Peretz T., Nori D., Hilaris B., et.al Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int.j.Rad,Oncol. Biol.Phys.1989; 17:931-935.
138. Abe M., Takahashi M., Yabumoto E., et.al. Clinical experiences with intraoperative of locally advanced cancer. Canc. 1980; 45:40-48.
139. Roldan G.E., Gundersen L.L., Nagorney D.M., et.al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Canc. 1988; 61:1110-1116.
140. Shibamoto Y., Manabe T., Baba N., et.al. High dose, external beam and intraoperative radiotherapy in the treatment of resectable and unresectable pancreatic cancer. Int.j..Rad.Oncol.Biol.Phys. 1990; 19:605-611.
141. Roldan G.E., Gunderson L.L., Nagorney D.M., et.al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic carcinoma. Canc. 1989; 61:1110.
142. Lionetto R., Pugliese V., Bruzzi P., et.al. No standart treatment is available for advanced pancreatic cancer. Eur.j.Canc. 1995; 6:882-887.
143. Climelius B., Hoffman K., Sjoden P.O., et.al. Chemotherapy improves survival and quality of life in advanced pancreatic cancer and biliary cancer. Ann Oncol. 1996: 7:593-600.
144. Гарин А.М., Хлебнов А.В. Справочник практической химиотерапии опухолей М., 1995.
145. Гарин А.М. Место и значение антиметаболитов в химиотерапии злокачественных опухолей. М., 1999.
146.Moertel C.G. Chemotherapy of gastrointestinal cancer. Clin.Gastr. 1976; 5:777-793.
147.Carter S.K., Comis R.L. The integration of chemotherapy into a combined modality approach for cancer treatment. Canc.Treat.Rev.1975; 2:193-214.
148. Schnall S., Macdonald J.S. Chemotherapy of adenocarcinoma of the pancreas. Sem.in Oncol. 1996; 23:2,220-228.
149. Ahlgren J.D. Pancreatic cancer . In "Chemotherapy of advanced disease". Eds. Ahlgren J.a Macdonald J., 1992; pp.227-235.
150. Ardalan B., Singh G., Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-asparatic. Acid in patients with advanced pancreatic and colorectal cancer. J.clin.Oncol.1988; 6:1053-1058.
151.Guevara S., et.al. Ambulatory treatment with 5-FU in prolonged continuous infusion for advanced adenocarcinoma. Proc.ESMO 1996; ab.247.
152. Marsh R.D.W., Manyam V., Bewsher C.,et.al. Circadian rhythm modulated 5-FUDR infusion with megace in the treatment of advanced pancreatic cancer. J.Surg Oncol., 1994;57:25-29.
153. Oman M., Blind P., Gustavsson B., et.al. Intraperitoneal 5-fluorouracil treatment in patients with non resectable pancreatic carcinoma. Proc. ECCO 9, ab.1280.
154.DeCaprio J.A., Mayer R.J., Gonin R., et.al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J.clin.Oncol. 1991; 9:2128-2133.
155. Pozzo C.. The Modulation of 5-fluorouracil with S-Leucovorin in the treatment of advanced pancreatic cancer: Only an attempt to improve quality of life. Proc. ESMO 1996, ab.252.
156. Morrell L.M., Bach A., Richman S.P., et.al. A phase II multi-institutional trial of low-dose N-(phosphanacetyl)L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. Canc. 1991; 67:363-366.
157. Ardalan B., Sridhar K.S., Benedetto P., et.al. A phase I, II study of high-dose leucovorin with low-dose phosphonace-tyl-L-aspartic acid in patients with advanced malignancies. Cancer 1991; 68:1242-1246.
158. Rosvold E., Schilder R.,Walczak J. et.al. Phase II trial of pala in combination with 5-fluorouracil in advanced pancreatic cancer. Canc.Chem.Pharm. 1992; 29:305-308.
159. Pazdur R., Ajani J.J., Abbruzzese J.L., et.al. Phase II evaluation of fluorouracil and recombinant 2a-interferon in pre-viously untreated patients with pancreatic adenocarcinoma. Canc. 1992; 70:2073-2076.
160. Scheithauer W., Pfeffel F.,, Komek G., et.al. A phase II trial of 5-fluorouracil, leucovorin and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Canc. 1992; 70:1864-1866.
161. Ikeda M., Okada S., Ueno H., et.al. A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. Proc. ASCO 1999, ab.1101.
162. Fiorentini G., Poddie D., Graziani G., et.al. Locoregional chemotherapy with mitomycin C administered as intra-aortic stop-flow infusion with hypoxic abdominal perfusion. Proc.ASCO 1997; ab.1024.
163. Moertel C.G., Schutt A., Reitemeier R.J., et.al. Therapy for gastrointestinal cancer with the nitrosoureas alone and in drug combination. Canc. Treal.Rep. 1976; 60:729-732.
164. Schein P.S., Lavin P.T., Moertel C.G., et.al. Randomized phase II study clinical trial of adriamycin , methotrexate and actinomycin D in advanced measurable pancreatic carcinoma. Canc.1978;42:19-26.
165. Yip D., Halford S., Karapetis C.. et.al. A phase II trial of callyx in the treatment of advanced pancreatic carcinoma. Proc.ASCO 1999, ab.1177.
166. Gastrointestinal Tumor study Group Phase II trials of the single agents baker's antifol, diaziguone and epirubicin in advanced pancreatic cancer. Canc.Treat.Rep. 1987; 71:865-867.
167. Cersosimo R.J., Hong W.K. Epirubicin .A review of the pharmacology, clinical activity ang adverse effect of an adriamycin analogue. J.Clin.oncol. 1986; 4:425-439.
168. Wils J., Bleiberg H., Blijham G., et.al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur.j.Canc.Clin.Oncol. 1985, 21:191-194.
169. Hochser H., Green M.D., Speyer J.L., et.al. Activity of epirubicin in pancreatic carcinoma. Canc.Treat.Rep. 1986, 70:299-200.
170. Loehrer P.J., Williams S.D. Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas. J.clin.Oncol. 1985; 3:367-372.
171. Ajani J.A., Abbruzzese L., Goudeau P., et.al. Ifosfamide and Mesna: Marginally active in patients with advanced carcinoma of the pancreas. J.Clin.Oncol. 1988; 6:1703-1707.
172. The Gastrointestinal Tumor study Group: Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Canc. 1989; 64:2010-2013.
173. Cerny T., Martinelli G., Goldhirsch A., et.al. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: A phase II study. J.Canc.Res.Clin.Oncol.1991; 117:135-138.
174. Wils J.A., Kok T., Wagener D.J.Th., et.al. Phase II trial with ifosfamide in pancreatic cancer. Eur.J.Canc. 1993; 29:290.
175. Judson I.R. Tomudex (raltitrexed) development: preclinical, phase I and II studies. Anticanc. drugs 1997; 8: suppl.2:5-9.
176. Pazdur R., Casper E.S., Meropol N.J., et.al. Phase II trial of tomudex a thymidilate synthase inhibitor in advanced pancreatic cancer. Proc.ASCO 1994; ab.613.
177. Pazdur R., Meropol N.J., Casper E.S., et.al. Phase II trial of zd 1694 (Tomudex) in patients with advanced pancreatic cancer. Invest.New Drugs 1995; 13(4):355-358.
178. Hanauske A.R. The development of new chemotherapeutic agents. Anticanc. Drugs 1996; 7(2):29-32.
179. Ota K., Taguchi T., Kimura K. Report on nationwide pooled data and cohort investigation in UFT Phase II study. Canc.Chem.Pharm. 1988:22:333-338.
180. Sadahiro S., Mukai M., Tokunaga N., et.al. Preliminary study of the new optimal dosage schedule for oral UFT. Proc.ASCO 1997; ab.726.
181.Orita K., Tanaka N., Goehi A., et.al. Clinical trial of immunochemotherapy with OH-I preparation (1NF-a) and UFT (uracil-tegafur) in unresectable pancreatic cancer. Proc.ASCO, 1995;ab.339.
182. Ardalan B., Sparling L., Livingstone A., et.al. Phase II trial of high-dose 24-hour infusion of 5-fluorodeoxyuridine in patients with inoperable pancreatic cancer (previously failed 5-FU and Gemzar). Proc.ASCO 1997, ab.999.
183. Wagener D.J., Verdonk H.E.R., Dirix L.Y., et.al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer. An EORTC Early Clinical Trials Group Study. Ann Oncol.1995; 6:102-104.
184. Sakata Y., Waku A., Nakao I., et.al. A late phase II study of irinotecan in advanced pancreatic cancer. Proc. ASCO, 1993, ab.633.
185. Brown T., Tangen C., Fleming T., et.al. A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc. ASCO 1993, ab.200.
186. Vеrweij J., Clavel N., Chevalier B. Paclitaxel (Taxol TN) and docetaxel (Taxotere) not simply two of a kind. Ann Oncol.1994; 5:495-505.
187. Okada S., Taguchi T. Phase II trial of docetaxel (taxotere) as first-line chemotherapy in patients with metastatic pancreatic cancer: a japanese cooperative study. Proc.ASCO 1998, ab.1019.
188. Rougier Ph., De Forni M., Adenis A., et.al. Phase II study of taxotere in pancreatic adenocarcinoma. Proc.ASCO 1994; ab.587.
189. Kouroussis Ch., Kakolyris S., Samelis G., et.al. Treatment of advanced pancreatic cancer with docetaxel. A multicenter phase II study. Proc.ASCO 1998; ab.1021.
190. Preusser P., Niederle N., Harstrick A., et.al. Phase II study of Docetaxel as first line chemotherapy in metastatic adenocarcinoma of the pancreas. Proc.ASCO 1999, ab.1142.
191. Heinemann V., Hertel L.W., Grindley G.B., et.al. Comparison of the cellular pharmacokinetics and toxicity of 2'2'-difluorodeoxycytidine and 1-b-D arabinofuranosylcytosine. Canc. 1988; 48:4024-4031.
192. Plunkett W., Huang P., Xu Y.Z., et.al. Gemcitabine: Metabolism, mechanism of action and self-potentiation. Sem.oncol. 1995, 22:4(suppl.11),3-10.
193. Heinemann V., Schulz L., Issels R.D., Plunkett W. Gemcitabine: A modulator of intracellular nucleatide and deoxynucleotide metabolism. Sem.oncol.,1995; 22:4( suppl 11), 11-18.
194. Гарин А.М., Базин И.С. Гемцитабин - новый перспективный препарат из группы антиметаболитов М., 1999.
195. Peters G. Antimetabolites. In "Oxford textbook of oncology". Eds.Peckham M., et.al., 1995; v.1, pp.524-552.
196. Casper E.S., Kelsen D.P., Kresek T., Tarassoff P. Gemcitabine (2'2'-difluorodeoxycytidine): evidence of activity in patients with adenocarcinoma of exocrine pancreas. Ann.Oncol. 1990; 1(suppl ):35.
197. Casper E.C., Green M.R., Brown T.D. Phase II trial of gemcitabine (2'2'-difluorodeoxycytidine) in patients with pancreatic cancer. Proc.ASCO, 1991; ab.440.
198. Casper E.S., Green M.R., Kelsen D.P., et.al. Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994; 12(1):29-34.
199. Carmichael J., Russel R.G., Spittle M.F., et.al. Phase II study of gemcitabine in chemonaive patients with pancreatic cancer. Ann.Oncol 1992; 3(suppl 5):190.
200. Fink U., Russel R.C., Spittle M.F., et.al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Eur.j.canc.1993; 29 (suppl.6) :101.
201. Carmichael J., Fink U., Russell R.G., et.al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br.j.Canc. 1996; 73:1, 101-105.
202.Rothenberg H.A., Burris H.A., Andersen J.S. Gemcitabine : palliative therapy for pancreas cancer patients failing 5-FU. Proc.ASCO, 1995, ab.470.
203. Andersen J.S., Burris H.A., Casper E., et.al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc, ASCO, 1994, ab.1600.
204. Moore M., Andersen J., Burris H., et.al. A randomized trial of gemcitabine versus 5-FU as first line therapy in advanced pancreatic cancer. Proc.ASCO, 1995, ab.473.
205. Rothenberg M.L., Moore M.J., Cripps M.C., et.al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann of oncol. 1996; 7:4, 347-353.
206. Storniolo A.M., Enas N.H., Brown C.A., Schilsky R. Treatment investigation new drug program for gemzar in patients with pancreatic cancer. Proc. ASCO, 1997; ab.1088.
207. Tempero M., Plunkett W., van Haperen V.R. Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed rate in metastatic pancreatic adenocarcinoma. Proc.ASCO 1999, ab.1048.
208. Weissmann L., Ludwig H. Intraarterial gemcitabine for treatment of inoperably pancreatic and cholongiocarcinoma. Proc. ASCO 1999, ab.1170.
209. Spagnuolo P., Roversi R., Rossi G., et.al. Phase II study of gemcitabine as locoregional treatment of advanced pancreatic cancer. Proc. ASCO 1999, ab.1153.
210. Rosemurgy L., Buckels J., Charnley R., et.al. A randomized study comparing marimastat to gemcitabine es first line therapy in patients with non-resectable pancreatic cancer. Proc. ASCO 1999, ab. 1005.
211. Evans T.R.J., Mansi J.L., Lofts F.J., et.al. EB-1089 (secalcitol) in pancreatic cancer. Preliminary results of an open uncontrolled phase II study . Proc. ASCO, ab.1085
212. Macdonald J.S., Wooley P.V., Smythe T., et.al. 5-fluorouracil, adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Canc. 1979; 44:42-47.
213. Smith F.P., Hoth D.F., Levin B., et.al. 5-fluorouracil, adriamycin and mitomycin C (FAM) chemotherapy for advanced adenocarcinoma of pancreas . Cancer 1980; 46:2014-2018.
214. Bitran J.D., Desser R.K., Kozloff M.F., et.al. The treatment of metastatic pancreatic and gastric adenocarcinoma with 5-fluorouracil, adriamycin and mitomycin C (FAM). Canc.Treat.Rep. 1979;63:2049-2051.
215. The Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma fluorouracil plus doxorubicin + mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J.Clin.Oncol 1986; 41:1794-1798.
216. Oster M.W., Gray R., Panasci L., et.al. Chemotherapy for advanced pancreatic cancer. Canc. 1986; 57:29-33.
217. Bukowski R.M., Schacter L.P., Groppe C.W., et.al. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C and strepto-zotocin (FAMS) in pancreatic carcinoma. Canc. 1982; 50:197-200.
218. Bukowski R.M., Fleming T.R., Macdonald J.S., et.al. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group Study . Canc. 1993; 71:322-325.
219. Karlin D.A., Strochlein J.R., Bennets R.W., et.al. Phase I-II study of the combination of 5-FU, doxorubicin, mitomycin C and semustine (FAMMC)in the treatment of adenocarcinoma of the stomach, gastroesophagel junction, and pancreas. Canc. Treat.Rep. 1982; 66:1613-1617.
220. Wiggans R.G., Wooley P.V., Macdonalds J.S., et.al. Phase II trial of streptozotocin, mitomycin C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Canc. 1978; 41:387-391.
221. Bukowski R.M., Balcerzoc S.P., O'Bryan R.M., et.al. Randomized trial of 5-FU and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Canc. 1983; 52:1577-1582.
222. Mallinson C.N., Rake M.O., Cocking J.B., et.al. Chemotherapy in pancreatic cancer: results of a controlled, prospective and randomized trial. Br.Med.j. 1980; 281:1589-1591.
223. Cullinan S., Moertel C.G., Wieand H.S., et.al. A phase III trial on the therapy of advanced pancreatic carcinoma. Canc. 1990; 65:2207-2212.
224. Kovach J.S., Moertel C.G., Schutt A., et.al. A controlled study of combined 1,3-bis-(2-chlorethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Canc. 1974; 33:563.
225. Buroker T., Kim P.N., Croppe C., et.al. 5-FU infusion with mitomycin C v.s. 5-FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. Canc. 1979; 44:1215-1221.
226. Horton J., Gelber R., Engstrom P., et.al. Trials of single agent and combination chemotherapy for advanced cancer of the pancreas. Canc.Treat.Rep. 1981; 65:65-68.
227. Bremer K. Primary treatment of advanced gastric and pancreatic adenocarcinomas with 5-fluorouracil, folinic acid and mitomycin C. Second international conference on biology, prevention and treatment of gastrointestinal malignancies; 1995; ab,57.
228. Maiello E., Gebbia V., Giuliani F., et.al. ELFE (etoposide, folinic acid, 5-fluorouracil and epirubicin, regimen in the treatment of advanced pancreatic cancer (APC). Proc.ECCO 9, 1997;p.280; ab.1270.
229. Di Costanzo F. Fluorouracil plus folinic acid vs 5-FU, FA and ifosfamide in advanced pancreatic cancer: a randomized phase II trial of the italian oncology group for clinical research. Proc.Second Int.Conf. Biol.Prev.Treat.Gastr.Malign., 1995; p.88
230. Ahmed F.Y., Michels J., Nicolson M.C. Preliminary results of a phase II study of infusional chemotherapy regimen MCF (mitomycin C., cisplatin and continuous infusional 5-fluorouracil) for pancreatic cancer. Proc. ASCO 1999, ab. 1059.
231. Moertel C.G., Rubin J., O'Connell M.J., et.al. A phase II stugy of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J.Clin.Oncol, 1986; 4:1053-1057.
232. Rougier Ph., Zarba J., Ducreux M., et.al. Efficacy of combined 5-FU and CDDP in advanced pancreatic adenocarcinoma. Int.Conf.Biol.Treat.Gastrointest. Malign.,1992; p.70
233. Rothman H., Cantrell J.E., Lokich J., et.al. Continuous infision 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Canc. 1991; 68:264-268.
234. Charles A., Heider A., Steffens F., et.al. 5-Fluorouracil|cisplatin in the treatment of advanced pancreatic cancer. Proc. ASCO 1999, ab.1076.
235. Rougier P., Ducreux M., Douillard J.Y., et.al. Efficacy of 5-FU+ cisplatin compared to bolus 5-FU in advanced pancreatic carcinoma:a randomized trial from the French anticancer centers digestive group. Proc. ASCO, 1999 ab.1050
236.Munzone E., Nole F., De Brand E., et.al. ECF (epirubicin, cisplatin, fluorouracil) in pancreatic carcinoma: a promising approach. Proc. ASCO 1997; ab.1062.
237. Underhill C.R., Highley M.S., Parnis F.X., et.al. Epirubicin, cisplatin and infusional 5-FU (ECF) - an active regimen in pancreatic carcinoma. Proc.ASCO 1996; ab.453.
238. Cantore A., Cavazzini G.,Aitine E., et.al. Intra-arterial chemotherapy for advanced carcinoma of the pancreas. Proc. ASCO 1996; ab.455.
239. Liu J.M., Chao Y., Tin G.M., et.al. Biweekly continuous infusion chemotherapy ( M-FLEEP) plus megestrol acetate for pancreatic cancer. Proc. ASCO 1999, ab.1119.
240. Dougherty J.B., Kelsen D., Kemeny N., et.al. Advanced pancreatic cancer. A phase I-II trial of cisplatin, high-dose cytarabine and caffeine. J.Nat.Canc.Inst. 1989; 81:1735-1738.
241. Hidalgo M., Paz-Ares L., Hitt R., et.al. Phase I-II study of gemcitabine combined with continuous infusion 5-fluorouracil as first-line chemotherapy in locally advanced and metastatic pancreatic cancer. Proc. ASCO 1997, ab.1030.
242. Gutzler F., Moehler M.,, Hosch W.P., et.al. A phase I study of gemcitabine in combination with 5 days 5 fluorouracil and folinic acid in patients with advanced adenocarcinomas of pancreas or bile duct. Proc. ASCO 1999, ab.1097.
243. Louvet C., Hammel P., Andre T., et.al. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treatment with a combination of leucovorin, 5-FU bolus and infusion and gemcitabine ( FOLFUGEM). Proc. ASCO 1999, ab.1054.
244.Oettle H., Pelzer U., Hochmuth K., et.al. Phase II trial of gemcitabine with 24-hour infusion of 5-fluorouracil and folinic acid in patients with advanced pancreatic cancer. Proc. ASCO 1999, ab. 1132.
245. Alabiso O., Grosso M., Buosi R., et.al. Locoregional chemotherapy for advanced pancreatic cancer: a phase I study. Proc. ASCO 1999, ab.1061.
246.Rodriguez-Lescure A., Carrato A., Massuti B., et.al. Phase I-II study of gemcitabine and weekly 48 hour continuous infusion if high dose 5-fluorouracil in advanced exocrine pancreatic cancer. Proc. ASCO 1999, ab.1145.
247. Villa E., Reni M. PEF-6 (cisplatin, epirubicin, 5-fluorouracil continuos infusion, gemcitabine): A new combination in advanced pancreatic adenocarcinoma: Phase II study . Proc. ASCO 1999, ab. 1033.
248. Heinemann V., Wilke H., Possinger K., et.al. Gemcitabine and cisplatin: combination treatment for advanced and metastatic pancreatic carcinoma. Proc. ASCO, 1996, ab. 623.
249. Heintmann V., Wilke H., Possinger K., et.al. Activity and tolerability of gemcitabine plus cisplatin in advanced metastatic pancreatic carcinoma. Proc. ECCO, 1997,ab.1240.
250. Heinemann V., Wilke H., Possinger K., et.al. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II study. Proc. ASCO 1999, ab. 1052.
251. Philip P.A., Zalupski M., Vaitkevicius V.K., et.al. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Proc. ASCO 1999, ab. 1053.
252. Colucci G., Riccardi F., Giuliani F., et.al. Randomized trial of gemcitabine alone or with cisplatin in the treatment of advanced pancreatic cancer: A phase II Multicenter Study of the Southern Italy Oncology Group. Proc. ASCO 1999, ab. 961.
253. Kakolyris S., Stathopoulos G., Tsavaris N., et.al. First line with docetaxel and gemcitabine in patients with advanced pancreatic cancer:a multicenter phase II study. Proc. ASCO 1999, ab.960.
254. Jacobs A.D., Otero H., Picozzi V., et.al. Gemcitabine and Taxotere in patients with unresectable pancreatic carcinoma. Proc. ASCO 1999, ab. 1103.
255. Muller H. Angiogenesis inhibition and intra-arterial chemotherapy- A new modality treatment for advanced and metastatic pancreatic carcinoma. Proc.ECCO 9 ,1997; ab.215.
256. Garcia A.L., Leichman A.A., Baranda J., et.al. Phase II study of trimetrexate (neutrexin), 5-fluorouracil and leucovorin in advanced pancreatic. Proc. ASCO 1999, ab.971.
257. Lersch C., Fckel F., Schutte-Flohlinde E., et.al. Phase II trial of cyclophosphamide , folinic acid, 5-fluorouracil, tamoxifen and gemcitabine in advanced pancreatic cancer. Proc. ASCO 1999, ab.1115
258. Brierley J., Oza A., Patnaik A., et.al. A phase I study of radiation therapy and gemcitabine in patients with locally advanced pancreatic carcinoma. Proc. ASCO 1999, ab.713.
259. McGinn C.J., Shureiqi I., Robertson J.M., et.al. A phase I trial of radiation dose escalation with full dose gemcitabine in patients with pancreatic cancer. Proc. ASCO 1999, ab.1051.
260.Kurtz J.E., Jung G.M., Rohr S., et.al. Combined Modality treatment for unresectable pancreatic cancer. Proc. ASCO 1999, ab. 1112
261. De Brand F., Orlando L., Drecchia R., et.al. Combined modality treatment for locally advanced pancreatic carcinoma ECF (epirubicin, cisplatin, fluorouracil as continuous infusion) plus concomitant three dimensional conformal radiotherapy. Proc. ASCO 1999, ab. 1125.
262.Childs H., Spenser S., Raben D., et.al. Phase I study of combined UFT plus leucovorin and radiation therapy in pancreatic cancer. Proc. ASCO 1999, ab. 956.
263. Brunson C.Y., Baron P., Leveen P., et.al. Phase I study of escalating tamoxifen, weekly low dose cisplatin and conformal radiation therapy in patients with locally advanced/unresectable pancreatic cancer. Proc. ASCO 1999, ab.788.
264. Osteen R.T., Zinner M.J., Fuchs C.S., et.al. Phase I trial of concurent gemcitabine, infusional 5-fluorouracil and radiation therapy in patients with locolized unresectable pancreatic adenocarcinoma. Proc. ASCO 1999, ab. 1091.
265.Safor A.M., Atamira P.S., Recht A. Phase I trial of gemcitabine , cisplatin and external beam radiation therapy for pancreatic cancer. Proc. ASCO 1999, ab.874.
266.Andren-Sandberg A., Johonsson S. Recurrence after total pancreatectomy in exocrine pancreatic cancer - liver metastases or local recurrence? Pancreas 1988; 3:590.
267. Tepper J., Nardi G., Sutt H. Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Canc. 1976; 37:1579.
268. Foo M.L., Gunderson L.L., Nagorney D.M., et.al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ±5-fluorouracil. Int.j.Rad.Oncol.Biol.Phys. 1993;26:483-489.
269. Whittington R., Bryer M.P., Haller D.G. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int. j.Rad.Oncol.Biol.Phys. 1991; 21:1137-1143.
270. Gastrointestinal Tumor Study Group: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch.Surg.1985; 120:899-903.
271. Klinkenbijl J., Sahmoud T., van Pel R., et.al. Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and peri ampullary region: A phase III trial of the EORTC GITCCG. Proc.ECCO 9 1997; ab.1239.
272. Kalser M.H., Ellenberg S.S. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch.Surg.1985; 120:899-903.
273. Yeo C.J., Cameron J.L., Lillemore K.D., et.al. Pancreaticoduodenectomy for cancer of the head of the pancreas; 201 patients. Ann.Surg.1995;221:721-733.
274. Amano H., Takada T., Kato H., et.al. Five-year results of a randomized study of postoperative adjuvant chemotherapy for resected pancreatic biliary carcinomas. Proc. ASCO 1999, ab.1049.
275. Spitz F., Abbruzzese J., Lee J., et.al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J. Clin.Oncol.1997; 15:928-937.
276. Thomas P.R.M. Radiotherapy for carcinoma of the pancreas. Sem.Oncol. 1996; 23:2,213-219.
277. Seydel H.G., Stablein D.M., Leichman L.P., et.al. Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The gastrointestinal tumor study group experience. Canc. 1990; 65:1478-1482.
278. Pilepich M.V., Miller M.H. Predoperative irradiation in carcinoma of the pancreas. Canc. 1980; 45:1945.
279. Wanebo H.J., Posner M., Glicksman A., et.al. Integrated modality protocol for carcinoma of the pancreas pilot.program. Proc.ASCO 1991, ab.499.
280. Hoffman J.P., Weese J.L., Solin L.J.,et.al. Preoperative chemoradiation for patients with resectable pancreatic adenocarcinoma: An Eastern Cooperative Oncology Group (ECOG) phase II study. Proc. ASCO 1995; ab.201.
281. Staley C.A., Lee J.E., Cleary K.R., et.al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am.j.Surg. 1996; 171:118-125.
282. Tyler D.S., Evans D.B. Reoperative pancreatoduodenectomy. Ann j.Surg. 1995;169:7-139.
283. Garton G.R., Gunderson L., Nagorne D.M., et.al. High dose preoperative external beam and IORT for locally advanced pancreatic cancer. Int.j.Rad.Oncol. Biol.Phys. 1993; 27-1153.
284. Bruckner H., Snady H., Dalton J., et.al. Split course radiotherapy effectively downstage and facilitate resection of unresectable pancreatic cancer. Proc.Eighth International congress on anti-cancer treatment 1997, ab.97.
285. Jessup J.M., Steele G., Mayer R.J., et.al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch.Surg. 1993; 128:559.
286. Scheithauer W., Pfeffel F., Koznek G., et.al. A phase II trial of 5-flourouracil, leucovorin and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Canc.70,1992; 1864-1866.
287. Jessup J.M., Mayer R.J., Posner M., et.al. Phase I/II neoadjuvant trials for locally advanced pancreas adenocarcinoma. Second intern. conf. on biol., prev. and treatment of gastrointestinal malign. 1995; ab 61.
288. Berns T. Prott F.J., Preusser P., et.al. Feasibility and phase II study of combined modality treatment with accelerated radiotherapy and chemotherapy in patients with localy advanced inoperable carcinoma of pancreas. Proc.ECCO 9 1997; ab. 1251.
289. Lorenz M., Janshon G., Heinrich S., et.al. Aorticstop-flow-infusion (ASF) in patients with unresectable pancreatic cancer. Proc. ECCO 9 1997; ab.1251.
290. Benz C., Hollander C., Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cyto-toxicity studies in human tumor cell lines. Canc.Res.1986; 46:2276-2281.
291. Andren-Sandberg A., Borg A., Dawiskiba S., et.al. Estrogen receptors and esrogen-binding protein in pancreatic cancer. Digest 1982; 35:12.
292. Lhoste E.T., Roebuck B.D., Brinck-Johsen T., et.al. Effect of castration and normal replacement on azaserin-induced pancreatic carcinogenesis in male and female Fisher rats. Carcinog. 1987; 8:696-704.
293 . Huguier M., Samama G., Testart J., et.al. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am j.Sur. 1992; 164:348-353.
294. Allegretti A., Lionetto R., Saccomanno S., et.al. LH-RH analogue treatment in adenocarcinoma of the pancreas. A phase II study. Oncol. 1993; 50:77-80.
295. Philip P.A., Carmichael J., Tonkin K., et.al. Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br.j.Canc. 1993; 67:379-282.
296. Wong A., Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. Canc. 1993; 71:2200-2203.
297. Bakkevold K.E., Pettersen A., Arnesjo B., et.al. Tamoxifen therapy in inresectable adenocarcinoma of the pancreas and the papilla of vater. Br.j.Surg. 1990; 77:725-730.
298. Keating J.J., Johnson P.J., Cochrane A.M.G., et.al. A prospective randomized trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br. J.Canc. 1989; 60:789-792.
299. Klijn J.C., Hoff A.M., Planting A.S., et.al. Treatment patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue sandostatin. A phase II study including endocrine effects. Br.j.Canc. 1990; 62:623-630.
300. Friess H., Buchler M., Beglinger C., et.al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancr. 1993; 8:540-545.
301. Caillouette C., Hammond C.L., Razvillas B., et.al. A phase I/II trial of SMS 201-995 pa Lar (SMS pa LAR) and gemcitabine in patients with advanced pancreatic cancer. Proc. ASCO 1999, ab.1071.
302. Abbruzzese J.L., Levin B., Ajani J.A., et.al. A pilot phase II trial recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: Results of a trial terminal by excessive toxicity. J.Biol.Resp.Mod. 1990; 9:522-527.
303. Tempero M.A., Sivinski C., Steplewski Z., et.al. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: Biological and clinical effects. J.Clin.Oncol.1990; 8:2019-2026.
304. Gottlinger H.G., Funke I., Johnson J.P. et.al. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int.j.Canc. 1986; 38:47-53.
305. Buchler M., Friess H., Schultheiss K.M., et.al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494(3L) in resectable pancreatic cancer. Canc. 1991; 68:1507-1512.
